Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.Septerna is working on G protein-coupled receptor (GPCR) drug discovery powered by its proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies.It has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three ...